FDA’s QUALITY ASSESSMENT SYSTEM
This article was originally published in The Gold Sheet
Executive Summary
...could include an expanded role for annual product reviews in the regulation of manufacturing changes as the new CMC review paradigm takes concrete form. In October, a large group of FDA and industry representatives gathered at a workshop designed to help guide the agency in addressing the practical issues and challenges involved in implementing the many dimensions of the quality assessment effort. The questions surrounding the concepts of design space, the pharmaceutical development report, the quality overall summary and the regulatory agreement – how they should be defined, reviewed, updated and interlinked – were among those that the participants wrestled with in trying to move the effort forward. [Summary reports delivered at the quality assessment workshop from breakout sessions on: * pharmaceutical development * CMC regulatory processes * CMC regulatory agreements * communication * design space * quality overall summaries * innovation and continuous improvement * post-marketing changes * integration of review and inspections * pharmaceutical assessment practices, and * quality-by-design implementation are included.]
You may also be interested in...
McKinsey Survey Highlights Progress, Challenges in Adoption of QbD
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Manufacturers Encouraged to Enhance Clinical Relevance of Quality With QbD
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
Biotech QbD Encounters Uncertainties Over Definitions and Regulatory Relief
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.